The main goal of this study is to consider SLC34A2 as a potential prognostic marker of oncological diseases using the mutational, expression, and survival data of cancer studies which are publicly available online. We collected data from four databases (cBioPortal, The Cancer Genome Atlas; cBioPortal, Genie; International Cancer Genome Consortium; ArrayExpress). In total, 111,283 samples were categorized according to 27 tumor locations. Ninety-nine functionally significant missense mutations and twelve functionally significant indel mutations in SLC34A2 were found. The most frequent mutations were SLC34A2-ROS1, p.T154A, p.P506S/R/L, p.G257A/E/R, p.S318W, p.A396T, p.P410L/S/H, p.S461C, p.A473T/V, and p.Y503H/C/F. The upregulation of SLC34A2 was found in samples of myeloid, bowel, ovarian, and uterine tumors; downregulation was found in tumor samples of breast, liver, lung, and skin cancer tumors. It was found that the life expectancy of breast and thymus cancer patients with an SLC34A2 mutation is lower, and it was revealed that SLC34A2 overexpression reduced the life span of patients with brain, ovarian, and pancreatic tumors. Thereby, for these types of oncological diseases, the mutational profile of SLC34A2 can be a potential prognostic marker for breast and thymus cancers, and the upregulation of SLC34A2 can be a potential prognostic marker for brain, ovarian, and pancreatic cancers.

The high mortality rate from ovarian cancer is due to the asymptomatic nature of the course of the disease, which leads to the diagnosis of ovarian cancer in later stages. The sodium-dependent phosphate transporter NaPi2b encoded by SLC34A2 gene is expressed in 80–90% of epithelial ovarian cancers and used as a target for therapeutic antibodies XMT-1536, and XMT-1592, which are derived from MX35 antibodies and used in clinical trials for the treatment of ovarian and lung cancers. In this work, we aimed to evaluate NaPi2b as a molecular marker for diagnostics and predicting the course and outcome of ovarian cancer disease. Quantitative analysis of SLC34A2 gene expression in ovarian tumor tissue was performed at the level of transcription and translation using real-time PCR, droplet digital PCR and Western blot analysis respectively. Statistical analysis was performed taking into account various clinicopathological characteristics of the ovarian cancer patients, including the stage of the disease, the tumor grade, the applying of neoadjuvant chemotherapy and the presence of ascites. In this work, we demonstrated that the expression of the human NaPi2b (hNaPi2b) transporter is downregulated in the tumors of patients receiving neoadjuvant therapy and during the development of disease. The data suggest that the level of expression of the SLC34A2 gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.

the tumor (CT), yielding a five-tiered classification (0e4). High IS values have been reported to predict improved outcomes in colorectal cancer. Methods:The cohort consisted of 52 TNBC patients (pts) who previously received neo-adjuvant anthracycline and taxane based chemotherapy. Quantitative analysis of the immune cells was carried out using a computer-assisted image analysis in different tumor locations for CD3 and CD8 T-cell markers. Additionally, we measured stromal TILs according to the internationals TILs working group. abstracts Annals of Oncology Volume 31 -Issue S5 -2020 S1227

No abstract

Background: SARS-CoV-2 Virus can trigger severe pneumonia and lead to acute respiratory distress syndrome. Data from clinical, in vitro, and in vivo suggest that virusinduced cytokine dysregulation is a contributory factor to the pathogenesis. Drugs targeting the same are being tried.Methods: To obtain a better understanding of the molecular events, we studied the transcriptome of infected macrophages and obtained a list of incriminated pathways using Gene Set Enrichment Analysis. Co-expression gene analysis was further used to predict drug targets. Results: Immune system, hemostasis, RNA metabolism, cellular response to external stimuli, vesicle-mediated transport, cell cycle mechanisms, DNA replication, and repair are upregulated. Interferon alpha, beta, and gamma are upregulated. IL-1,6,10, 13, TNF NF-KB are upregulated. Signaling by non-receptor tyrosine kinase, NOTCH, Sonic Hedgehog, lLeptin, MAP kinase-6, 4, and estrogen-mediated signaling are increased. Olfactory sensation, transmission across chemical synapses, and sperm motility appear to be downregulated. Disease host signature has resemblance with cystic fibrosis, thrombophilia, leishmania, influenza, CMV, HIV and SARS infection, and diseases of programmed cell death like neurodegenerative diseases. We have predicted 24 precise drugs which can be explored in clinical trials of SARS-CoV 2 treatment. Conclusions:Our study provides important mechanistic insights into the understanding of SARS-CoV-2 viral pathogenesis and the multi-faceted host immune responses.Legal entity responsible for the study: AIIMS Bhopal.